State of the Union Address Investing Idea: Precision Medicine
There are plenty of companies developing precision medicine drugs already, and investors would be wise to watch key players.
3 Warning Signs You've Invested in a Dangerous Biotech Stock
Three Motley Fool analysts help investors spot biotech stock warning signals.
Will Organovo Holdings Inc. be Bought Out in 2015?
It could happen, but here's why long-term investors should ignore this noise anyway.
Can You Guess Which Big Pharma Has a More Robust Pipeline Than Pfizer, Inc.?
Pfizer's pipeline currently features 86 clinical studies and/or registrations. That's an incredible figure that demonstrates Pfizer's commitment to R&D. But, it's also not the most robust pipeline in the pharmaceutical sector. Can you guess which big pharma company has an even larger pipeline than Pfizer?
Why Shares of Foundation Medicine, Inc. Skyrocketed Today
Shares of cancer diagnostic maker Foundation Medicine more than doubled Monday morning. Here's why.
Why ImmunoGen, Inc. Stock Was Decimated in December
ImmunoGen was the worst biotech stock in December after it and its partner Roche released disappointed study data. Find out whether the mauling was merited or if ImmunoGen shares could be a bargain here.
What's the Next Stop for Inovio: $5 or $15?
With its shares up 500% over the past two years, is Inovio poised for more upside or a 50% haircut?
Could These Tiny Biotech Stocks Double in 2015?
Ophthotech Corporation, Achillion Pharmaceuticals, and Portola Pharmaceuticals all have catalysts that could lift shares in 2015.
3 Value Stocks Near 52-Week Lows Worth Buying
These three value stocks have been beaten up recently, but there's a chance they may not stay near their 52-week lows for much longer.
3 Biotech Stocks I Don't Want for Christmas
I’d prefer coal in my stocking to these three troubled biotech stocks.